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Abstract.  The capacity of cells to interact with the 
plasminogen activator, urokinase, and the zymogen, 
plasminogen, was assessed using the promyeloid 
leukemic U937 cell line and the diploid fetal lung 
GM1380 fibroblast cell line. Urokinase bound to both 
cell lines in a time-dependent, specific, and saturable 
manner (Kd  =  0.8-2.0 nM).  An active catalytic site 
was not required for urokinase binding to the cells, 
and 55,000-mol-wt urokinase was selectively recog- 
nized.  Plasminogen also bound to the two cell lines in 
a  specific and saturable manner. This interaction oc- 
curred with a  Kd of 0.8-0.9  IxM and was of very high 
capacity (1.6-3.1  x  107 molecules bound/cell). The in- 
teraction of plasminogen with both cell types was par- 
tially sensitive to trypsinization of the cells and re- 
quired an unoccupied high affinity lysine-binding site 
in the ligand. When plasminogen was added to the 
GM1380 cells, a  line with high intrinsic plasminogen 
activator activity, the bound ligand was comprised of 
both plasminogen and plasmin. Urokinase, in catalyti- 
cally active or inactive form, enhanced plasminogen 
binding to the two cell lines by 1.4-3.3-fold.  Plasmin 
was the predominant form of the bound ligand when 
active urokinase was added, and preformed plasmin 
can also bind directly to the cells. Plasmin on the cell 
surface was also protected from its primary inhibitor, 
a2-antiplasmin. These results indicate that the two cell 
lines possess specific binding sites for plasminogen 
and urokinase, and a  family of widely distributed cel- 
lular receptors for these components may be consid- 
ered.  Endogenous or exogenous plasminogen activators 
can generate plasmin on cell surfaces, and such activa- 
tion may provide a  mechanism for arming cell sur- 
faces with the broad proteolytic activity of this 
enzyme. 
XPRESSION of specific proteinase activities at cell sur- 
faces is a phenotypic feature of a variety of cells and 
is a frequently elicited response of cells to stimula- 
tion and transformation (22, 32, 33, 36).  Plasminogen acti- 
vators (PA) l are among the most broadly distributed of such 
cell surface proteinases (27, 37, 39, 40).  Urokinase (UK) is 
representative of one of the two major types of PA enzymes. 
This type of PA is expressed by a variety of cells including 
many tumor cells (3, 27, 37) and activated mononuclear cells 
(27, 33, 36).  UK is highly specific for plasminogen and can 
activate the zymogen to plasmin by cleavage of a single pep- 
tide bond (26).  Plasmin, in addition to its primary role in the 
proteolysis of fibrin, is a broad spectrum proteinase which 
may participate in such general functions as cell migration 
and differentiation, tissue remodeling, and inflammation (9, 
17, 25). Control of UK synthesis and secretion and produc- 
tion of specific inhibitors of PA and plasmin are identified 
1. Abbreviations used in this paper:  6-AHA, 6-aminohexanoic acid; DIP- 
plasmin and DIP-UK, diisopropylphosphoryl-plasmin and -urokinase ob- 
tained by treating plasmin or UK with 5 mM diisopropyl fluorophosphate; 
PA, plasminogen activator;  UK, urokinase. 
mechanisms for regulation of the proteolytic activity of the 
plasminogen system. Recently, evidence has been provided 
for the presence of specific binding sites for UK on cell sur- 
faces, suggesting a previously unconsidered mechanism for 
the regulation of the plasminogen system. Vassalli et al. (34) 
showed the presence of specific binding sites for UK on the 
U937 cell line which has certain monocyte-like properties, 
and on human peripheral blood monocytes; Del Rosso et al. 
(6) demonstrated the interaction of this ligand with 3T3 cells 
and a Rous sarcoma transformed line of 3T3 cells; and Sto- 
pelli et al. (29) demonstrated that the UK binding capacity 
of U937 cells could be regulated with phorbol myristate ace- 
tate. Taken together, these studies provide direct evidence for 
the existence of  cell surface binding sites for UK. The results 
of  these studies differ with regard to the requirement for cata- 
lytically active UK in the interactions. U937 cells bind both 
active and diisopropyl fluorophosphate-treated UK (34), and 
this interaction is apparently mediated by the amino-terminal 
region of the ligand (29). In contrast, binding to the 3T3 cells 
requires an active catalytic site in the enzyme (6). 
In this study, we show for the first time that nucleated cells 
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presence of specific UK binding sites on two cell types:  a 
catalytically active enzyme is not required for these interac- 
tions. These same cells not only bind plasminogen and UK, 
but also  UK influences plasminogen binding to the cells, 
raising the possibility of a plasmin-generating system on cell 
surfaces. Evidence is also presented to indicate that plasmin 
may remain cell surface associated, suggesting a mechanism 
to arm the cell with the broad proteolytic activity of this en- 
zyme. Finally, cell-bound plasmin is protected from its pri- 
mary inhibitor, ct2-antiplasmin. 
A preliminary report of this work was presented at the Xth 
Congress  of the International  Society of Thrombosis and 
Haemostasis,  San Diego, CA, July  1985. 
Materials and Methods 
Proteins 
Glu-plasminogen was purified from fresh frozen human plasma by affinity 
chromatography on lysine-Sepharose followed by gel filtration  (7).  The 
characteristics of the plasminogen used in this study in both nonlabeled and 
radiolabeled form have been previously described (19). UK, predominantly 
of 55,000  mol  wt,  was purified  from Winkinase (125,000  CTA  U/mg), 
provided by Winthrop Laboratories, New York,  NY, by affinity chromatog- 
raphy on benzamidine-Sepharose (37).  ~2sI-UK was prepared by a  modi- 
fied chloramine T labeling procedure (16) with specific activities of 1-3 I.tCi/ 
p.g. As reported by Pannell and Gurewich (23),  radioiodination of UK re- 
suited in some loss of enzymatic activity. As determined by the capacity of 
~2sI-UK to activate plasminogen as measured with the tripeptide substrate 
$2251  (30) (Helena Laboratories, Beaumont, TX), the radiolabeled prepa- 
rations used in this study retained 23-34 % of enzymatic activity. Although 
Coomassie Blue staining after SDS PAGE showed only minimal amounts 
of low molecular weight UK within the preparations used, autoradiography 
of t25I-UK indicated the presence of this species. Therefore,  for selected 
experiments, particularly for Scatchard analyses, low molecular weight UK 
within the ~2sI-UK preparation was removed by gel filtration on Sephadex 
G-/5.  DIP-UK was prepared  by  treating  ~2sI-UK or  UK with  5  mM di- 
isopropyl fluorophosphate for 60 min at 22°C. Using a synthetic substrate 
assay (30), the extent of inactivation by diisopropyl fluorophosphate was at 
least 95%.  ¢t2-Antiplasmin (lot No.  5/21/85)  was purchased from Ameri- 
can Diagnostica Inc., Greenwich, CT. 
Cell Culture and Ligand Binding Assays 
Two model cell lines were used in this study: the myeoplasma-free human 
myeloid leukemic cell line, U937, was provided by Dr. Hillel Koren of Duke 
University and was used to permit comparison of the UK binding data with 
that of Vassalli et al.  (34);  the diploid fetal lung fibroblast cell line, GM 
1380, was obtained from the Genetic Mutant Repository, Camden, NJ. Both 
cell  lines express cell  associated PA activity as determined on  ~2Sl-fibrin 
plate assays in the presence of plasminogen (33). The PA activity of the GM 
1380 cells was 5-10-fold greater than that of the U937 cells; i.e.,  l0 times 
more U937 cells were required to release the same amount of radioactivity 
from the fibrin plates within the same time period (3 h). 
U937 cells were grown in RPMI  1640 containing 10%  FCS. For use in 
ligand binding assays, the cells were washed three times in RPMI 1640 and 
resuspended to a  final concentration of 1  x  107/ml (as determined with a 
bemocytometer) in RPMI 1640 containing 0.05 M Hepes, pH 7.4, and 0.1% 
BSA.  ~25I-UK or  125I-plasminogen  was added,  maintaining a  total  vol of 
0.2-1.0 ml. At selected time points, triplicate 50-I.tl aliquots were removed 
from the mixtures, layered onto 300 p.I of 20% sucrose, and centrifuged for 
2 min in a Beckman micmfuge. Tips of the centrifuge tubes were amputated 
and counted for radioactivity. On the basis of protein determinations of cell 
pellets, recoveries of the U937 cells exceeded 95 %. For studies with the GM 
1380 cells, the cells were seeded into six (3.4 cm i.d.) or 12 (2.2 cm) Costar 
wells (Costar, Cambridge, MA) at 4  or  !  ×  lO  s cells/well,  respectively. 
The cells were grown in DME containing 10% FCS for 3-4 d at which time 
confluence was reached. Before use, the medium was removed, and the cells 
were washed twice with DME. Ligand binding was measured in DME con- 
taining 0.1% BSA, maintaining a total vol of 1 ml in the 6-well and 0.4 ml 
in the t2-well plates. Radiolabeled ligands were added and, at selected time 
points, fluid was removed by aspiration, and the cells were washed twice 
with DME. Cell-bound radioactivity was then extracted in 0.1%  SDS.  In 
selected experiments, the cell-bound radioactivity was extracted first with 
1% deoxycholate and then with SDS to distinguish cell surface-associated 
from matrix-bound ligand (18).  GM  1380 cell concentrations were deter- 
mined on the basis of DNA content (8) of selected wells in each experiment, 
and DNA content was converted to cell number based on a determined value 
of 21 pg DNA per cell. For selected experiments, the U937 and GM 1380 
cells were cultured for 3-4 d  in FCS which had been acidified at pH 3.2 
for 2 h to destroy certain plasmin inhibitors (33) and depleted of plasmino- 
gen by passage over lysine-Sepharose. By immunodiffusion analysis with 
an antiserum reactive with bovine plasminogen, the extent of plasminogen 
depletion exceeded 90%.  In addition, for experiments in which the effect 
of the lysine analog, 6-aminohexanoic acid (6-AHA), on the interactions 
was tested, binding was measured in Hank's balanced salt solution (Gibco, 
Grand Island, NY) containing 0.03 M Hepes, pH 7.3, to exclude lysine from 
the  medium.  In  binding  experiments,  cytolysis was determined by  cell 
counting, cytotoxicity on the basis of trypan blue exclusion, and degradation 
of ligands by changes in the precipitability of radioactivity in 15 % TCA. The 
latter analysis was performed by extracting the cell-bound ligand with 0.1% 
SDS at selected time points and subjecting the extract to precipitation with 
15%  TCA for 20-30 min at 4°C. 
Molecules of ligand bound per cell were calculated based on the specific 
activities of each ligand. Specific binding was measured as the difference 
in the radioactivity bound to the cells in the presence and absence of a 50- 
fold molar excess of nonlabeled ligand.  Dissociation constants (KdS) were 
determined from specific binding isotherms using a nonlinear curve-fitting 
computer program, Ligand, of Munson and Rodbard (21) as previously ap- 
plied in studies of plasminogen binding to platelets (19). Where indicated, 
results are reported as means -I-  SD.  Linear correlation coefficients were 
calculated with a TI-55-II calculator (Texas Instruments Inc., Dallas, TX). 
SDS PAGE 
Cell-bound ligands were extracted with 2% SDS which solubilized >--95% 
of the radioactivity and the extracts were boiled for 5 min before electropho- 
resis. SDS PAGE was performed on 8  ×  10 cm vertical slab gels. UK was 
analyzed on  10%  polyacrylamide gets under nonreducing conditions and 
plasminogen on 7 % gels under reducing conditions in the buffer system of 
Laemmli (12). The plasmin/ct2-antiplasmin complex (see Fig. 7) was ana- 
lyzed on 6 % polyacrylamide gels in the buffer system of Weber and Osborn 
(38).  Gels were stained with Coomassie Blue, dried,  and autoradiograms 
were developed with XRP-I film (Eastman Kodak, Rochester, NY). The au- 
toradiograms were scanned using a Zeineh soft laser densitometer equipped 
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Figure  1.  Time  courses  of  ~25I-urokinase  and  ~251-plasminogen 
binding to U937 and GM  1380 cells at 37°C.  '25I-UK in active or 
inactive (DIP-UK) form were added at 0.5 nM. Excess nonlabeled 
UK was used at 500 nM to assess the saturability of binding.  ~2Sl- 
Plasminogen was added at 0.1  pal and nonlabeled plasminogen at 
20 laM.  For U937 cells, bound ligand from free ligand was sepa- 
rated  by  centrifugation  through  20%  sucrose.  For  the GM  1380 
cells, the cell monolayer was washed by aspiration, and the bound 
ligand was extracted with  SDS. 
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weights were estimated relative  to standard  proteins obtained from Sigma 
Chemical Co.  (St.  Louis, MO). 
Results 
As shown in Fig.  1, the human myeloid leukemic cell line, 
U937,  and the diploid  fetal fibroblast cell line,  GM  1380, 
bound  ~25I-UK in a  time-dependent manner at 37°C.  With 
both cell lines, binding was rapid and reached apparent equi- 
librium within  5  min.  DFP-treated  L~sI-UK alSO bound  to 
both cell lines, and the rate and extent of binding were simi- 
lar to that observed with the untreated  ligand.  Binding  of 
12sI-UK to the cells was saturable as indicated by the capac- 
ity of excess nonlabeled UK to inhibit binding of the radiola- 
beled  ligand.  At the  input  concentration  of esI-UK used, 
0.5 nM, inhibition by a 50-fold molar excess of nonlabeled 
UK at a 30-min time point was 90% for the U937 cells and 
92 % for the GM  1380 cells.  Binding of untreated or DFP- 
treated ~2sI-UK was inhibited by either nonlabeled DIP-UK 
or active UK, exceeding 85 % in all cases. As shown in Fig. 
l, C and D, these same cell lines were also capable of binding 
tESI-plasminogen.  U937 and GM 1380 cells bound  ~2SI-plas- 
minogen with a similar time course and apparent equilibrium 
was attained within 30-60 rain. This interaction was also in- 
hibited by excess nonlabeled plasminogen,  indicating only 
low levels of nonsaturable binding. 
The specificity of the interactions of m25I-UK  and 125I-plas- 
minogen with the cells was determined by assessing the ca- 
pacity of a panel of unrelated proteins to inhibit binding of 
the radiolabeled ligands. As noted above and verified in Ta- 
ble I, a  50- to  100-fold  molar excess of nonlabeled UK or 
plasminogen produced >83 % inhibition of the binding of the 
respective radiolabeled ligands to either cell line. At a  100- 
fold or greater molar excess, myoglobin, immunoglobulin G, 
transferrin, fibrinogen, and ovalbumin produced <11% inhi- 
bition of the binding of 125I-UK and <19 % inhibition of 125I- 
plasminogen binding to the two cell lines. 
Table I. Specificity of Urokinase and Plasminogen 
Binding to U93 7 and GM1380 Cells 
Inhibition of binding (%) 
Nonlabeled 
proteins  U937  GM 1380 
Urokinase 
Myoglobin  0 (+ 11)  0 
IgG  7  10 
Transferrin  0 (+8)  11 
Fibrinogen  6  0 (+1) 
Ovalbumin  0  0 (+6) 
Urokinase  88  94 
Plasminogen 
Myoglobin  0  2 
IgG  19  0 
Transferrin  15  6 
Fibrinogen  0 (+1)  3 
Ovalbumin  0 (+6)  0 (+10) 
Plasminogen  92  83 
1251-UK and ~2SI-plasminogen  were present at 2 nM and 100 nM, respectively. 
The nonlabeled proteins were at final concentrations of 2-10 p.M. Binding at 
37°C was measured after 30 min for 125I-UK and 60 rain for 12SI-plasminogen. 
The numbers in parentheses indicate the extent of increased UK- or plasmino- 
gen-binding to the cells in the presence of the added nonlabeled proteins rela- 
tive to the absence of the proteins. 
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Figure 2.  Scatchard plots for the binding of urokinase  and plas- 
minogen to the U937 and GM 1380 cells. The data points for these 
plots  were derived  from specific binding  isotherms  for the  two 
ligands with each cell type. Binding isotherms for UK were con- 
structed by adding varying amounts of ~25I-DIP-UK  to the cells in 
the presence or absence of excess nonlabeled DIP-UK. Plasmino- 
gen binding isotherms were obtained by adding varying amounts of 
nonlabeled  plasminogen  (0.1-20 pM)  and  a  constant  amount 
of tracer 125I-plasminogen (0.1 p.M) to the cells.  UK binding was 
measured at 30 min at 37°C. Plasminogen binding was measured 
at 60 min at 37°C. 
Reversibility of the interactions of plasminogen and UK 
with the two cell lines was demonstrated,  t25I-Plasminogen 
was incubated with the cells for 30 min, and a 50-fold molar 
excess of nonlabeled plasminogen was then added.  In the 
next 60  min,  >75%  of the  ~25I-plasminogen  bound  to the 
U937 and GM 1380 cells was displaced. Under the same con- 
ditions, buffer alone caused a 25-35 % dissociation of bound 
plasminogen. Thus, the reversibility of plasminogen binding 
to  these  cells  is  similar  to  that  previously observed with 
platelets  (19).  In  a  similar  experimental  format,  within 
30 min, excess nonlabeled UK displaced >60%  of the IzsI- 
UK prebound to the cells for 20 min. Equivalent (fourfold) 
dilution with buffer alone caused <5 % dissociation, consis- 
tent with a high affinity interaction. 
With evidence of specificity, saturability, and reversibility, 
binding  parameters  for  the  interactions  of ~2sI-UK (DFP- 
treated) and  ~25I-plasminogen with the U937 and GM  1380 
cells were derived. Two experimental formats were used to 
construct  specific binding  curves at  37°C  for each ligand 
with each cell line.  With  ~25I-DIP-UK, varying concentra- 
tions of the radiolabeled ligand  in the range of 0.1-20 nM 
were added to the cells in the presence or absence of 750 nM 
nonlabeled DIP-UK. Specific binding curves were then de- 
rived by subtracting binding observed in the presence of ex- 
cess nonlabeled UK from that observed in its absence.  To 
construct plasminogen binding isotherms, a constant amount 
of tracer ~25I-plasminogen at 0.1  ILM was added in combina- 
tion with increasing concentrations of nonlabeled plasmino- 
gen in the range of 0.1-20 pM plasminogen.  This protocol 
was used to limit the addition of excessive radioactivity to the 
cells.  Nonspecific  binding  was  estimated  experimentally 
from the residual binding in the presence of the highest con- 
centration of nonlabeled plasminogen (20 pM) or as a fitted 
parameter in  the  Ligand  computer program.  Values  esti- 
mated for the nonspecific binding of plasminogen were very 
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GM 1380  U937 
Parameter  UK  Plasminogen  UK  Plasminogen 
Kd  0.8  +  0.5 nM  0.9  +  0.4 I.tM  2.0  +  1.6 nM  0.8  +  0.5  gM 
Sites/Cell  2.6  +  0.8  ×  105  3.1  +  0.4  x  107  5.0  +  2.9  x  104  1.6 +  1.4  x  107 
Degradation *  1.6 %/h  0.4 %/h  2.0 %/h  0.8 %/h 
These results are based on at least four determinations with each ligand and each cell line. 
* Based on the decrease in precipitability in 15% TCA of the cell-associated ligands over a 3-h period at 37°C. 
similar  by these  two approaches.  The data obtained  from 
these  analyses  were  used  to  construct the  Scatchard  plots 
shown in Fig. 2. The binding of UK and plasminogen to both 
cell types was best described by straight lines as linear corre- 
lation  coefficients  exceeded  r  =  0.99.  Thus,  these  results 
suggest the presence of a  single class of binding sites with 
respect to affinity for each ligand with each cell line. 
Values  for  the  binding  parameters  obtained  from  the 
Scatchard plots have been summarized in Table II. UK bound 
to both the GM 1380 and U937 cells with a similar apparent 
Kd,  but the GM  1380 cells  had a  fivefold higher capacity. 
The binding parameters obtained for the U937 cells (Kd  = 
2 nM; sites  =  50,000) are similar to those reported by Vas- 
salli et al.  (34) (Kd  =  0.4 nM;  sites  =  60,000).  Plasmino- 
gen  interacted  with  both  cell  lines  with  similar  binding 
parameters.  The  Kd  determinations  for  these  interactions 
were the same, and the number of sites differed by less than 
twofold. The rates of degradation of bound ligand indicated 
in Table II are based upon the changes in the precipitability 
of the cell-bound radioactivity in  15 %  TCA during  3  h  at 
37°C. Under these conditions, neither plasminogen nor UK 
was significantly degraded by either cell line.  FCS,  which 
was used to maintain the two cell lines, contains plasminogen 
and plasmin inhibitors.  To determine if their presence could 
influence the binding parameters  measured,  the cells  were 
grown  for  3--4 d  in  FCS  depleted  of plasminogen  on  ly- 
sine-Sepharose  affinity  columns  and  acidified to denature 
certain  plasmin  inhibitors  (33).  tzsI-Plasminogen and  ~5I- 
UK binding to these cells was then measured, and Scatchard 
plots were constructed.  The binding parameters determined 
were  identical  to those derived  for cells  grown in the un- 
treated  FCS. 
The GM  1380 and U937 cells used in this  study express 
PA activity. U937 cells have been shown to synthesize a PA 
inhibitor which forms a complex with UK that is at least par- 
tially stable in SDS (34, 35). Therefore, possible modifica- 
tions of the  125I-plasminogen and  125I-UK ligands bound to 
the  two  cell  lines  were  considered.  ~25I-plasminogen  and 
125I-UK were bound under equilibrium conditions to the two 
cell  lines,  and  the bound  ligands  were extracted  from the 
cells and subjected to SDS PAGE analyses (Fig. 3). Under re- 
ducing conditions, single chain plasminogen (Mr =  92,000) 
is readily distinguished  from the plasmin heavy chain (Mr 
=  60,000). No plasmin was detected in the uSI-plasminogen 
preparation added to the cells,  and the ligand bound to the 
U937  ceils  remained  predominantly  plasminogen  ('~90% 
based on densitometric scans). In contrast, partial activation 
of the  ligand  bound  to  the  GM  1380 cells  was  observed. 
Based upon the estimated molecular weights of 94,000 for 
the upper band and 62,000 for the lower band, these deriva- 
tives were identified as plasminogen and the plasmin heavy 
chain, and these were present in approximately equal quan- 
tities on the GM 1380 cells at 60 min. The extent of plasmin 
formation on the GM 1380 cells was time dependent.  As es- 
tablished  by densimetric  scans  of autoradiograms  such  as 
shown in Fig. 3, at 0.5 h, 71%  of the cell-bound ligand was 
plasminogen, and this decreased to 33% by 4 h. This time- 
dependent change in plasmin formation was also observed in 
the unbound fraction but at a slower rate. Thus, the GM 1380 
cells mediated a  slow rate of plasmin formation in the free 
and cell-bound material.  At no time point was formation of 
an SDS-stable complex between the plasmin light chain and 
a  cellular inhibitor on the cells or in the soluble phase de- 
tected.  To  characterize  the  ~25I-UK bound  to  the  cells,  a 
ligand preparation containing both the high and low molecu- 
lar weight forms of UK was used to determine  if the cells 
could discriminate  between these  forms.  As shown in Fig. 
3, 55,000-mol-wt UK was selectively bound to the U937 and 
GM  1380 cells.  Formation of an SDS-stable complex with 
a molecular weight higher than that of free UK was not de- 
tected. 
Figure 3.  Characterization  of the ligands,  J25I-urokinase and  t25I- 
plasminogen, added and bound to the U937 and GM 1380 cells on 
SDS PAGE. The ligands bound to the cells for 60 min at 37°C were 
extracted with 2 % SDS with >/95  % solubilization  of radioactivity. 
The extracts were subjected  to SDS PAGE and compared with the 
added  ligands.  ~25I-Plasminogen samples  have  been  run  on  7% 
polyacrylamide gels under reducing conditions,  and ~25I-UK  sam- 
ples have been run on 10% polyacrylamide gels under nonreducing 
conditions.  The autoradiograms of the gels are shown. Lanes A, B 
and C are the added ligand, the ligand bound to the U937 cells, and 
the ligand bound to the GM  1380 cells,  respectively.  As estimated 
from the mobilities  of the bands relative  to protein  standards,  the 
estimated  molecular weights of the proteins  were, for plasminogen 
in lane A, 94,000; for plasmin heavy chain in lane  C, 62,000;  for 
high and low molecular weight UK in lane A, 54,000 and 34,000, 
respectively. 
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Molecules bound/cell 
U937  Cells  GM1380 Cells 
125I-Ligand  37°C  4°C  37°C  4°C 
Urokinase  24,500 +  7,500  21,300 :t: 3,500  32,700 5:4,300  5,000 + 450 
Plasminogen  68,400 +  3,500  17,000:1:2,300  75,600 +  8,100  64,800 5:600 
~25I-UK or 125I-plasminogen  was added at 0.5 nM and 50 nM, respectively, to the cells pre-equilibrated at 37 ° or 4°C. UK binding was measured at 20 min and 
plasminogen binding at 60 min. 
The similarity in the apparent dissociation constants of UK 
and of  plasminogen for the two cell lines suggests that similar 
mechanisms  may be  involved in  the  interaction  of these 
ligands with each cell line. The effect  of  temperature on bind- 
ing of t25I-UK and L25I-plasminogen to U937 and GM  1380 
cells is shown in Table HI and indicates that the binding sites 
mediating these interactions are not precisely identical. UK 
binding to the U937 cells was minimally affected by tempera- 
ture as the extent of the interaction was similar at 37°C and 
4°C. This result is consistent with previously reported data 
on the temperature sensitivity of UK binding to these cells 
(29). In contrast, t25I-UK binding to the GM 1380 cells ex- 
hibited a marked temperature dependence. 12~I-UK binding 
to the GM 1380 cells at 4°C was only 15% of the level ob- 
served at 37°C.  Time course experiments indicated that UK 
binding to the GM 1380 cells reached apparent equilibrium 
within 20 min at both temperatures so that the decrease in 
binding at 4°C was not attributable to a slower rate of ligand 
binding.  Binding of 125I-plasminogen to the two cell lines 
showed an entirely different pattern of temperature sensitiv- 
ity. Interaction of this ligand with the GM 1380 cells was rel- 
atively temperature insensitive, whereas binding to the U937 
cells was temperature sensitive. The extent of plasminogen 
binding to the U937 cells was fourfold higher at 37°C than 
at 4°C. By Scatchard analyses, it was determined that this 
difference was a consequence of a decrease in the number of 
plasminogen binding sites at 4°C, and the affinity of the in- 
teraction was the same at the two temperatures. 
The sensitivity of plasminogen and UK binding to trypsin 
treatment of the cells is summarized in Table IV. The cells 
were treated with 500 I.tg/ml trypsin for 30 min at 37°C, and 
the  enzyme was  neutralized  with  excess  soybean trypsin 
inhibitor  before  addition  of  t25I-UK or  125I-plasminogen. 
Trypsin treatment decreased UK binding to both cell lines 
by >81%. This decrease was not a result of cytolysis, cytotox- 
icity, or proteolysis of the ligand (as measured by changes 
in  the precipitability of the ligand  in  TCA).  Plasminogen 
binding to both cell lines exhibited a partial sensitivity to 
trypsinization.  Trypsin  treatment  decreased  plasminogen 
binding by 40 and 33%  to the GM  1380 and U937 cells, 
respectively. This partial sensitivity may reflect incomplete 
proteolysis of the plasminogen binding sites or their micro- 
environment at  the  time  and/or  concentration of trypsin 
selected or a decrease in the affinity of the receptors due to 
proteolysis. Treatment of the GM  1380 cells with trypsin 
caused their release from the culture wells, and the results 
shown in Table IV were obtained by measuring the binding 
of the ligands to the cells in suspension. In view of the de- 
crease in the capacity of  the suspended GM 1380 cells to bind 
both ligands, the contribution of the subcellular matrix to the 
binding of plasminogen and urokinase to these cells was as- 
sessed.  125I-Plasminogen or 125I-UK were bound to the at- 
tached GM  1380 cells for 60 min at 37°C.  Rather than ex- 
tracting the bound ligands with SDS,  1% deoxycholate was 
used, under the conditions described by McKeown-Longo 
and  Mosher  (18),  to  selectively extract cell surface-asso- 
ciated L~5I-plasminogen or ~25I-UK. Treatment with deoxy- 
cholate extracted >90 % of the ligands specifically bound to 
the GM 1380 cell monolayers, excluding a significant contri- 
bution of the extracellular matrix to the observed binding of 
plasminogen and UK to these cells. 
Plasminogen binding to platelets is inhibited by tz-amino- 
carboxylic acids such as 6-AHA (19). These compounds in- 
teract with the lysine-binding sites associated with the krin- 
gle  structures of plasminogen  (28).  As  shown in  Fig.  4, 
6-AHA also inhibited the binding of plasminogen to U937 
and GM 1380 cells. This inhibition was dose dependent, and 
occurred in a similar concentration range.  50 % inhibition 
was obtained at 2.5 and 10 ~tM 6-AHA for the GM 1380 and 
U937  cells,  respectively.  As  the  Kd  for  the  high  affinity 
lysine-binding site of plasminogen is "~9 laM compared to 
5 mM for the low affinity lysine-binding sites (15), the data 
suggest that the high affinity site must be unoccupied for in- 
teraction of plasminogen with the cells to occur. The binding 
Table IV.  Effect of Trypsin  Treatment of U937 and GM1380 Cells on Their Capacity to Bind Urokinase and Plasminogen 
Molecules bound/cell 
Plasminogen  Urokinase 
Treatment  U937  GM 1380  U937  GM t 380 
Untreated  55,400  +  6,200  86,200  +  4,500  36,600  5:800  44,800  5:3,500 
Trypsin  37,100  +  1,400  51,700  +  5,800  3,200  5:800  3,800  +  800 
The cells were treated with 500 ttg trypsin in 0.5 mM EDTA for 30 min at 37°C. This treatment resulted in detachment of the GMI380 cells. Soybean trypsin 
inhibitor at 0.5  mg/ml was added;  and  after 10 min, the cells were washed three times by centrifugation.  Binding was measured by addition of 100 nM  ~25I- 
plasminogen or 0.5 nM  t25I-UK to the cell suspensions  at 37°C. UK binding was measured at 20 rain and plasminogen binding at 60 rain.  Treatment of the ceils 
with EDTA alone caused minimal changes in the binding of the two ligands to either cell line. 
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Figure 4. The effect of 6-AHA on the binding of 125I-plasminogen 
to the U937 (solid square) and GM 1380 (solid circle) cells.  ~25I- 
Plasminogen (0.1 wM) and varying concentrations of 6-AHA were 
added to the cells, and binding was measured after 60 min at 37°C. 
Percent inhibition was calculated relative to plasminogen binding 
in the absence of the lysine analogue. At the highest concentration 
used (50 I.tM), 6-AHA was not cytotoxic, cytolytic, did not cause 
detachment  of the GM  1380 cells,  and did not affect binding of 
t25I-UK to the GM 1380 (open circle) or U937 cells (open square) 
at 20 minutes at 37°C. The experiments were performed in Hanks' 
balanced salt solution to exclude lysine from the medium. 
of UK, which also contains kringle structures (11), was not 
affected by 6-AHA. 
The influence of one fibrinolytic component on the bind- 
ing of the other to the cell lines was assessed. Experiments 
were performed in  which  t25I-DIP-UK  (0.5  nM)  and  125I- 
plasminogen (0.1 p,M) were added to the cells in the presence 
of a  high concentration  of nonlabeled DIP-UK (1  l~Vl) or 
plasminogen (10 IxM). As summarized in Table V, plasmino- 
gen had only minimal effects on UK binding to the cells. No 
effect of plasminogen was observed on UK binding to the 
GM 1380 cells, whereas a slight inhibition of binding (31%) 
was observed on UK binding to the U937 cells. In contrast, 
UK exerted a marked effect upon  125I-plasminogen  binding 
to the cells. With both cell lines, UK was found to enhance 
plasminogen binding.  UK at  1 paM enhanced plasminogen 
binding to the U937 cells by  1.4-fold and to the GM  1380 
cells by 3.3-fold.  As the enhancement was more extensive 
with the GM 1380 cells, this effect was further explored using 
these cells. The UK-induced increase in plasminogen bind- 
ing to the GM 1380 cells was consistently observed in nine 
consecutive  experiments.  The  extent  of the  increase  was 
somewhat variable and ranged from  1.7- to 6.3-fold (com- 
pared to binding in the absence of UK). The enhancement 
was also observed with both active and DIP-UK. As shown 
in Fig.  5,  the enhancement of ~25I-plasminogen binding to 
the GM 1380 cells was dependent upon the concentration of 
UK added. Enhanced plasminogen binding was observed at 
UK concentrations >1 nM and was maximal at 500 nM UK. 
As noted in Fig. 5, at a 10-nM concentration DIP-UK and ac- 
tive  UK were equally  effective in  enhancing  plasminogen 
binding. This was also observed at a higher concentration of 
UK; at 1 laM, the increase in plasminogen binding induced 
by active UK was 3.7  +  1.7-fold and by DIP-UK was 3.0  + 
2.0-fold. 
Potential mechanisms for the augmented binding of plas- 
minogen in the presence of UK were considered.  As a first 
possibility, we considered whether the enhanced binding was 
related to plasmin formation or binding to the cells. No en- 
Table V. Effect of Nonlabeled Plasminogen 
and Urokinase on the Binding of 1251-Urokinase and 
125I-Plasminogen  to U937 and GM1380 Cells 
Relative binding 
~zSI-plasminogen  t25i_urokinas  e 
Nonlabeled 
protein  U937  GMI380  U937  GMI380 
Plasminogen (I0 ~tM)  19.6  14.4  69.0  94.3 
DIP-UK (1  ~tM)  140.3  334.8  8.3  9.7 
Binding of ~25I-plasminogen  (100 nM) and ~2SI-DIP-UK  (0.5 nM) to the cells 
was measured at 60 and 20 rain,  respectively,  in the presence or absence of 
nonlabeled plasminogen and DIP-UK.  Results are calculated relative to sam- 
ples lacking the nonlabeled proteins which have been assigned values of 100. 
zymatic activity was detected in the DFP-treated UK prepa- 
rations, but low levels of residual activity could form plasmin 
which could be preferentially bound to the cells. To test this 
possibility,  125I-plasminogen  was  bound  to  the  GM  1380 
cells in the presence of 100 or 500 nM UK or DIP-UK. Plas- 
minogen binding was enhanced 1.9-2.5-fold at 60 min under 
these conditions. The radiolabeled ligand bound to the cells 
was then extracted and analyzed on SDS  PAGE.  The gels 
shown in Fig.  6  indicate that the DFP-treated UK did not 
cause an increase in the proportion of plasmin associated 
with the cells.  The ratio of plasminogen to plasmin heavy 
chain bands bound to the GM 1380 cells was the same in the 
presence  or  absence  of DIP-UK.  Thus,  UK-induced  en- 
hancement of plasminogen binding is not dependent upon 
plasmin formation. When active UK was added,  all of the 
bound ligand was plasmin.  This latter result indicates that 
plasmin can be directly expressed on the cell surface. 
To determine if plasmin can interact preferentially with the 
cells, the binding properties of radioiodinated DIP-plasmin 
were analyzed. As summarized in Table VI, at input concen- 
trations of 0.1  p.M, DIP-plasmin and plasminogen bound to 
the U937 ceils to a similar extent. At a 10-fold excess, nonla- 
beled plasmin and plasminogen inhibited the binding of both 
ligands to a  similar degree,  indicating that plasmin bound 
specifically to the cells and that the ligands competed for the 
same set of binding sites. DIP-plasmin binding was also in- 
hibited by 6-AHA, implicating the lysine-binding sites in the 
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Figure 5.  Enhancement of plasminogen binding to the GM  1380 
cells  by varying  concentrations  of DIP-UK.  'zsI-Plasminogen at 
0.1  pA,  l and varying concentrations of DIP-UK were added to the 
GM 1380 cells at 37°C, and specific plasminogen binding was mea- 
sured after 60 min. The single point (open circle) was obtained by 
addition of active UK. 
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were also obtained with the GM 1380 cells.  Thus, plasmin 
can bind directly to the cells via the sites which also recog- 
nize plasminogen. 
To consider whether the basis for enhanced plasminogen 
binding to the cells in the presence of UK was due to an in- 
crease in the affinity or number of plasminogen binding sites, 
the binding of varying concentrations of plasminogen to the 
GM 1380 cells was measured in the presence or absence of 
1 IxM DIP-UK. The specific binding isotherms derived are 
shown in Fig. 7. The differences in the extent of plasminogen 
binding in the presence or absence of UK were greater at the 
lower  concentrations  of  added  plasminogen  and  became 
similar at high concentrations of added ligand.  These data 
suggest that the total number of plasminogen-binding sites 
was very similar in the presence or absence of UK but the 
apparent  affinity  of  plasminogen  for  the  cells  increased 
slightly in the presence of UK. Scatchard analyses of these 
results were consistent with this interpretation; namely, the 
affinity of the cells for plasminogen increased by approxi- 
mately threefold in the presence of UK. 
The above analyses suggest that plasmin can be formed on 
cell  surfaces  and  remain  cell  surface  associated.  Plasmin 
(and  plasminogen)  binds  to  ¢t2-antiplasmin,  the  primary 
plasmin inhibitor, via its high affinity lysine-binding site be- 
fore interacting with the active site of the enzyme (4). As the 
data shown in Fig. 4 suggest that the binding of plasminogen 
to the GM 1380 and U937 cells is dependent upon the lysine- 
binding  sites,  protection  of cell-bound  plasmin  from  ct2- 
antiplasmin  was examined,  t25I-Plasminogen (50  nM)  was 
Table VI. Comparison of  Plasminogen and 
DIP-Plasmin Binding to U937 Cells 
]~I-Ligand bound (molecules/cell) 
Inhibitor  DIP-Plasmin  Plasminogen 
None  330,800 +  27,500  390,000  +  32,300 
Piasminogen (1  gM)  46,500  +  8,700  64,200 +  6,500 
DIP-Plasmin (1  gM)  48,200  +  10,600  82,500  +  6,800 
6-AHA (0.2 M)  6,400  +  800  7,700 +  700 
t25I-plasminogen or ~25I-DIP plasmin were added to the U937 cells at 100 nM 
in the presence or absence  of the indicated  competitors. Binding  was measured 
after a 60-min incubation at 37°C. 
bound to the GM 1380 cells for 60 min at 37°C and then a 
high concentration of streptokinase (75 U/ml) was added to 
fully convert bound and free plasminogen to plasmin. After 
an additional  30 min at 37°C,  a2-antiplasmin was added at 
final concentrations of 100 or 25 nM. After 30 min, the cell- 
bound and unbound  ligands  were analyzed by SDS  PAGE 
on 6% polyacrylamide gels under nonreducing conditions. 
Autoradiograms of the gels are shown in Fig. 8. At both con- 
centrations  of ct2-antiplasmin,  formation of a  plasmin/a2- 
antiplasmin complex (Mr  150,000)  was apparent in  the su- 
pernatant. In contrast, the plasmin/ct2-antiplasmin complex 
was not observed with cell-bound material; only the single 
band  of plasmin  (Mr  89,000)  was detected.  In control ex- 
periments,  it was determined  that  the  addition  of ctz-anti- 
plasmin did  not  alter the  amount of cell-associated radio- 
activity; i.e., the complex did not selectively dissociate from 
the cells. Thus, cell-associated plasmin was protected from 
its primary plasma inhibitor,  a2-antiplasmin. 
Discussion 
In this study, we have demonstrated that two established cell 
lines interact with two central components of the fibrinolytic 
system, the plasminogen activator, urokinase, and the zymo- 
gen,  plasminogen.  Binding  of UK to U937  cells has been 
previously demonstrated (29,  34),  and the binding param- 
Figure  6.  Characterization  by  SDS  PAGE of  125I-plasminogen 
bound to the GM 1380 cells in the presence or absence of UK and 
DIP-UK.  ~25I-Plasminogen  was bound to the cells  for 60 rain at 
37°C and then bound ligand was extracted and analyzed by SDS 
PAGE as indicated in Fig. 3. Lanes are as follows: (A) added plas- 
minogen;  (B) bound ligand in absence of added UK;  (C) bound 
ligand with 0.5 p.M DIP-UK added;  (D) bound ligand with  1 pal 
DIP-UK added;  (E)  bound  ligand with 0.5  IxM UK added;  (F) 
bound ligand with  1 IxM UK added. 
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Figure 7. Binding of plasminogen to the GM 1380 cells in the pres- 
ence and  absence of urokinase.  Varying  concentrations of non- 
labeled plasminogen with a  constant amount of ]25I-plasminogen 
tracer  were  added  to  the  cells  with  or  without  1  I.tM DIP-UK 
present. Binding was measured after 60 min at 37°C. The data was 
analyzed in the Ligand computer program to estimate nonspecific 
binding and to construct the specific binding isotherms shown. 
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~25I-Plasminogen at 50 nM was incubated with the GM 1380 cells 
for 60 min at 37°C. Streptokinase (75 U/ml) was added; and, after 
30 min at 37°C, Ctz-antiplasmin  was added. After a 30-min incuba- 
tion, the supernatant was removed, the cells were washed once, and 
were extracted with SDS. Supernatants and cell extracts were boiled 
at the same time and analyzed by SDS PAGE (6% gels under non- 
reducing conditions). Lanes A and C are the supernatants obtained 
with the ct2-antiplasmin at 100 and 25 nM,  respectively. Lanes B 
and D are the corresponding cell extracts. Lane E is plasmin formed 
from ~25I-plasminogen  with the dose of streptokinase used. The es- 
timated molecular weight of  plasmin was 89,000 and of the plasmin 
a2-antiplasmin complex,  150,000. 
eters that we derived were similar to those reported by Vas- 
salli et al. (34) and Stopelli et al. (29). Our observation that 
UK also specifically binds to GM  1380 cells demonstrates 
that a distinct cell type also possesses UK receptors. Binding 
of UK to both U937 and GM  1380 cells did not require an 
active catalytic site within the enzyme, consistent with the 
observations of Vassalli et al. (34) and Stopelli et al. (29) and 
distinct from the interactions described by Del Rosso et al. 
(6).  Moreover, the affinity of UK for the two cell lines was 
similar. Thus, the possibility of widely distributed binding 
sites for UK which interact with this PA with similarly high 
affinities may be considered.  The fact that  ~25I-UK, which 
retained 23-34% of its plasmin-activating activity, and DIP- 
UK, which had no detectable residual activity (<5 %), bound 
to both cell types in an identical manner suggests that the 
affinity of the receptor system for active and inactive UK can- 
not be significantly different. 
The two cell lines exhibiting UK binding properties were 
also  capable of specifically interacting  with  plasminogen. 
The affinity and capacity of the two cell lines for plasmino- 
gen were quite similar. The similarity in binding parameters 
was observed although the methods used to separate bound 
from free ligand were quite different for the two cell types, 
suggesting that relatively low affinity interactions can be ana- 
lyzed by these approaches. The low affinity of these interac- 
tions  is also  similar to that determined  for the  binding  of 
plasminogen to platelets (19). It should be noted, that if the 
existence  of plasminogen-binding  sites  on  U937  cells  is 
reflective of their monocyte-like properties (indeed, we have 
obtained  preliminary  evidence  to  indicate  that  monocytes 
can bind  plasminogen  [19, and  our unpublished  results]), 
monocytes are exposed to a plasma environment containing 
~2 lxM plasminogen (5). The capacity of both cell lines for 
plasminogen was very high and is in a range similar to that 
reported for the number of elastase- and lactoferrin-binding 
sites on macrophages (2).  6-AHA inhibited the binding of 
plasminogen to the U937 and GM 1380 cells. This inhibition 
was observed in a  concentration range consistent with oc- 
cupancy of the high affinity lysine-binding site (15) which is 
associated with the  first kringle of plasminogen  (13). The 
failure of fibrinogen at 5 gM to inhibit plasminogen binding 
to the cells presumably reflects the low affinity of fibrinogen 
for the high affinity lysine-binding site of plasminogen (14). 
Similar results with respect to the involvement of the high 
affinity lysine-binding site and the failure of fibrinogen to in- 
hibit binding have also been obtained for the interaction of 
plasminogen with platelets (19). Thus, as suggested for the 
UK-binding  sites,  plasminogen-binding  sites  may also  be 
widely distributed.  Moreover, these binding sites appear to 
require  an unoccupied high affinity lysine-binding  site for 
recognition of plasminogen. Consistent with this hypothesis 
is our preliminary data indicating that a variety of peripheral 
blood cells may bind plasminogen (19),  and the presence of 
plasmin-binding sites on endothelial cells (1). 
UK increased plasminogen binding to both U937 and GM 
1380 ceils.  The extent of this increase was  1.4-fold for the 
U937 cells and 3.4-fold for the GM 1380 cells. Enzymatically 
active UK was not required for this augmentation, suggesting 
that conversion of plasminogen to plasmin was not essential 
for inducing increased ligand binding. SDS PAGE and direct 
analyses of the binding of plasmin to the cells verified this 
conclusion. The increase in plasminogen binding in the pres- 
ence of UK may reflect an increase in the apparent affinity 
or the number of binding sites for the ligand on the cells. The 
data support the former possibility by suggesting that there 
is a slight increase in the affinity of plasminogen for the GM 
1380 cells in the presence of UK. Such a change in affinity 
could arise either from an interaction of UK with plasmino- 
gen resulting in enhanced binding of such a complex to the 
cells or from an alteration of the plasminogen-binding sites 
due to occupancy of the UK receptor.  The effect of UK on 
plasminogen binding was saturable with respect to UK con- 
centration,  and  the  increase  in  plasminogen  binding  was 
observed in a  range consistent with occupancy of the  UK- 
binding site.  Thus,  the data is consistent with communica- 
tion between the UK- and plasminogen-binding sites. 
Analyses of the ligand bound to the GM  1380 cells indi- 
cated  that  plasmin  as  well  as  plasminogen  can  become 
directly associated with the cells. Plasmin could be formed 
in the soluble phase and then associate with the cell surface. 
If  this is the mechanism for plasmin association with the cell, 
then the interaction of both plasmin and plasminogen with 
the cells must occur with similar affinity to account for the 
linearity that the Scatchard plots obtained.  Consistent with 
this interpretation is the data demonstrating that plasmin and 
plasminogen bind to the same set of sites (Table VI). An al- 
ternative mechanism for detection of plasmin on the cell sur- 
face  is  that  bound  plasminogen  is  activated  by  the  ex- 
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In either case, it is clear that plasmin can remain cell surface 
bound. Indeed, when active UK was added to the GM 1380 
cells,  virtually all of the cell-associated ligand bound at 60 
min was plasmin. Thus, the presence of plasmin(ogen) bind- 
ing sites provides a means for cells to convert their intrinsic 
PA activity, with restricted substrate specificity, to the broad 
proteolytic activity of the enzyme plasmin. Once plasmin is 
formed or binds on the cell surface, it is protected from its 
primary inhibitor, ct2-antiplasmin,  relative to free plasmin. 
On this basis, local proteolysis could be achieved in an envi- 
ronment rich  in plasmin  inhibitors.  While  further studies 
will be necessary to establish the accessibility of the active 
site of plasmin bound to the cellular receptor to low and high 
molecular weight substrates, the binding of DIP-plasmin to 
the cells  indicates that the active site of the enzyme is not 
directly involved in the interaction. 
We have shown that plasminogen binds to platelets through 
two distinct  mechanisms  (20).  One pathway  is  dependent 
upon platelet fibrin which is expressed on the cell surface as 
a consequence of thrombin stimulation. The U937 and GM 
1380  cells  did  not express  fibrinogen-related  antigens  on 
their  cell  surfaces  as  detected  with  radiolabeled  F(ab')2 
fragments of an antiserum reactive with the D and E regions 
and  carboxy-terminal  region  of  the  Act  chain  of  bovine 
fibrinogen. The second pathway of plasminogen binding to 
platelets is dependent on membrane glycoprotein GPIIb/IIIa. 
We  have  identified  molecules  immunologically  related  to 
GPIIb/IIIa  on U937 and GM 1380 cells (24). GPIIb/IIIa-re- 
lated molecules have also been demonstrated on endothelial 
cells (10, 31).  These molecules appear to be similar, but are 
not precisely identical. As noted in this study, the UK- and 
plasminogen-binding sites on the two cell lines studied are 
similar to one another with respect to their affinity for the 
ligands,  their sensitivity to trypsinization, and, in the case 
of plasminogen, with respect to the requirement for an un- 
occupied high affinity lysine-binding site for the ligand. Nev- 
ertheless,  the binding sites for each ligand on the two cell 
lines are not precisely identical based upon the differential 
sensitivities of the interactions to temperature.  Thus, it be- 
comes an interesting avenue of investigation to explore the 
relationship between this family of related, but not necessar- 
ily  identical,  cell  surface  molecules  and the plasminogen- 
and urokinase-binding sites on these cells. 
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